Skip to main content

Malvern company gets FDA approval for injectible drug to treat cellulite

The company plans to delay the launch of the product until next year because of Covid-19's impact on physician offices and consumer spending.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.